Jardiance now force to be reckoned with in heart failure

7 March 2022

Boehringer Ingelheim and Eli Lilly’s (NYSE: LLY) Jardiance (empagliflozin) has been granted a marketing authorization by the European Commission (EC) for the treatment of adults with symptomatic chronic heart failure.

Originally approved in diabetes, the SGLT2 blocker has become an increasingly valuable product for the development partners, with approvals in heart failure offering the potential for continued expansion.

With demand soaring, Lilly alone took in close to $1.5 billion sales for the therapy in 2021, an increase of 29% on the year before, with $807 million coming from the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK